Disease Info Card

Ischemic Cardiomyopathy

Information about Ischemic Cardiomyopathy: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Ischemic Cardiomyopathy

Most recent studies have shown that Ischemic Cardiomyopathy shares some biological mechanisms with angina-pectoris, cardiac-arrhythmia, cardiac-failure-chronic, cardiac-fibrillation, cardiomyopathies, cardiomyopathy-dilated, cardiomyopathy-familial-idiopathic, coronary-artery-disease, coronary-heart-disease, heart-diseases, heart-failure, infarction, ischemia, mitral-valve-insufficiency, myocardial-infarction, myocardial-ischemia, regurgitation, tachycardia-ventricular, ventricular-dysfunction, ventricular-dysfunction-left.

Among the many pathways, these few ones have gauged particular interests from scientists studying Ischemic Cardiomyopathy, and have been seen in publications frequently: Aging, Angiogenesis, Cell Cycle, Cell Death, Cell Proliferation, Coagulation, Fatty Acid Oxidation, Hibernation, Immune Response, Inflammatory Response, Innervation, Localization, Pathogenesis, Programmed Cell Death, Regeneration, Translation, Transport, Vasculogenesis, Vasoconstriction, Vasodilation

Quite a number of genes have been found to play important roles in Ischemic Cardiomyopathy, such as ACE, AGT, CALCR, CALR, CFH, CRP, GNL3, GZMA, IL6, KRAS, NDUFB6, NPPB, SLC17A5, SLC6A8, TNF, VEGFA. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.